MRCP for Cholangiocarcinoma and Viability of Artificial Intelligence to Oncological Care in Pakistan: A Case Report and Literature Review
International Research Journal of Oncology,
Introduction: Cholangiocarcinoma (CCA) is a primary malignancy arising from cholangiocytes of the biliary tract. In majority of the cases, late presentations are noted, where there is vascular encasement with perineural and lymphatic invasion. Curative resection with negative tumor margins is a viable option in only 30% patients.
Objective: To describe a clinical case of cholangiocarcinoma with respect to the diagnostic radiological perspective and radiomics-artificial intelligence in Pakistan.
Case Presentation: A 60 years old male patient visited a tertiary care hospital with complaints of jaundice, weight loss and off and on fever over past few months. On MRCP, moderate intra and extrahepatic biliary dilatation with abrupt, irregular narrowing of proximal common bile duct revealing a ‘gloved finger appearance’ was documented. The coronal reformatted MRCP imaging findings showed intrahepatic biliary duct dilatation with abrupt irregular cut off at the proximal CBD. The diagnostic radiological findings pointed to a malignant stricture, possibly cholangiocarcinoma. On obtaining biopsy proceedings of the suspicious mass, a final diagnosis was made of adenocarcinoma of the common hepatic duct (cholangiocarcinoma). While the patient ultimately underwent surgery at the hospital, there was loss to follow-up post diagnostic radiological/pathological confirmation of the case, and surgical intervention.
Conclusion: While we relied on MRCP findings, the conventional imaging choice for CCA, we envision that AI, a novel technique, will be an essential step in radiological diagnosis, oncological prognosis, and surgical treatment options. Radiomics knowledge systems are a technology of the future that will help in primarily identifying, segmenting, and extracting features from regions of interest.
- artificial intelligence
How to Cite
DOI: 10.1055/s-0040-1719188 Epub 2020 Dec 11. PMID: 33328703; PMCID: PMC7732564.
Zhang A, Liu B, Xu D, Sun Y. Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: A case report. Medicine (Baltimore). 2019;98(52):e18435.
DOI: 10.1097/MD.0000000000018435. PMID: 31876723; PMCID: PMC6946271.
Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011 ;54(1):173-84.
DOI: 10.1002/hep.24351 PMID: 21488076; PMCID: PMC3125451.
Kumar S, Masood N, Shaikh AJ, Valimuhammad AT, Haider G, Lal A, Niamatullah N. Clinical presentation and outcomes of patients with biliary malignancies: The Aga Khan University experience. Asian Pac J Cancer Prev. 2009;10(3):463-6. PMID: 19640192.
Yang CM, Shu J. Cholangiocarcinoma evaluation via imaging and artificial intelligence. Oncology. 2021;99(2): 72-83.
DOI: 10.1159/000507449 Epub 2020 Nov 4. PMID: 33147583.
Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168-79.
DOI: 10.1016/S0140-6736(13)61903-0 Epub 2014 Feb 26. PMID: 24581682; PMCID: PMC4069226.
Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95-111.
DOI: 10.1038/nrclinonc.2017.157 Epub 2017 Oct 10. PMID: 28994423; PMCID: PMC5819599.
Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer. 2016; 122(9):1349-69.
DOI: 10.1002/cncr.29692 Epub 2016 Jan 22. PMID: 26799932.
Malaguarnera G, Paladina I, Giordano M, Malaguarnera M, Bertino G, Berretta M. Serum markers of intrahepatic cholangiocarcinoma. Dis Markers. 2013;34(4):219-28.
DOI:10.3233/DMA-130964 PMID: 23396291; PMCID: PMC3809974.
Sarfraz Z, Sarfraz A, Iftikar HM, Akhund R. Is COVID-19 pushing us to the Fifth Industrial Revolution (Society 5.0)? Pak J Med Sci. 2021;37(2):591-594.
DOI:10.12669/pjms.37.2.3387 PMID: 33679956; PMCID: PMC7931290.
Abstract View: 87 times
PDF Download: 45 times